Cue Biopharma Inc expected to post a loss of 16 cents a share - Earnings Preview

Cue Biopharma

24/03/2025 20:17

Cue Biopharma Inc CUE.OQ CUE.O is expected to show a fall in quarterly revenue when it reports  results on March 26 (estimated) for the period ending December 31 2024

The Boston Massachusetts-based  company is expected to report a 6.6% decrease in revenue to $1.701 million from $1.82 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Cue Biopharma Inc is for a loss of 16 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Cue Biopharma Inc is $4.00​, above​ its last closing price of $0.98. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.20
-0.19
-0.17
Beat
11.7
Jun. 30 2024
-0.28
-0.28
-0.20
Beat
29.6
Mar. 31 2024
-0.28
-0.28
-0.25
Beat
11.3​
Dec. 31 2023
-0.28
-0.28
-0.29
Missed
-4.3
​​Sep. 30 2023
-0.30
-0.34
-0.24
Beat
29.9
Jun. 30 2023
-0.30
-0.30
-0.29
Beat
4.9​
Mar. 31 2023
-0.32
-0.29
-0.29
Met
0
Dec. 31 2022
-0.29
-0.31
-0.38
Missed
-22.6

This summary was machine generated March 24 at 20:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)